Latest Europe News

ECS Botanics reports a third straight quarter of positive operating cash flow, driven by strong B2C growth and strategic international shipments to Germany and New Zealand.

PYC Therapeutics has gained Orphan Drug Designation from the European Medicines Agency for its VP-001 candidate targeting Retinitis Pigmentosa type 11, enhancing its regulatory and commercial pathway in Europe.

AML3D has maintained a steady $2.2 million quarterly revenue run rate and secured $12.5 million in new orders during 3Q26, pushing its total orders for FY2026 to $29 million. The company is aggressively expanding its US manufacturing footprint and making initial inroads into UK and European defence markets.

Imricor Medical Systems updates its SEC Form 10 with minor SEC-driven revisions as it pushes forward with FDA clearances and clinical trials, reporting a $25.3 million net loss in 2025 amid early-stage commercialisation.

The FDA has removed the postmarketing cardiac repolarization study requirement for Clinuvel's SCENESSE®, reflecting confidence in its long-term safety profile. This marks a regulatory milestone for the only approved treatment for erythropoietic protoporphyria in the US.

Nordic Resources (ASX:NNL) has completed its assay reporting for the 2025 Kopsa drilling program, revealing a new higher-grade stockwork zone and multiple mineralised extensions outside current resource boundaries. Drilling has resumed at Kopsa and Kiimala, with metallurgical testing underway and an updated resource estimate due in Q3 2026.

Sarytogan Graphite Limited has upgraded its Central Graphite Zone resource, marking a key milestone with Measured classification and progressing its Definitive Feasibility Study. Meanwhile, copper exploration reveals promising anomalies, backed by fresh capital injections.

Neuren Pharmaceuticals reported a solid A$30.4 million net profit in 2025, powered by a 15% rise in DAYBUE® royalties. The company is progressing its NNZ-2591 Phase 3 trial for Phelan-McDermid syndrome and has initiated a share buy-back amid perceived undervaluation.

Infinity Metals continues to push forward with exploration in Australia while awaiting critical mining licence feedback for its San Jose Lithium Project in Spain amid regional government delays.

Macallum New Energy has successfully listed on the ASX and raised A$7.4 million to fund exploration in the Northern Perth Basin. The company is progressing a 66% complete Barberton 3D seismic survey and preparing a Condor 2D survey, positioning itself amid renewed regional drilling activity.

Elementos Limited has made significant strides in developing its tin and tungsten assets, with progress on Oropesa’s permitting and a major resource upgrade at Cleveland. A $29.5 million strategic placement bolsters its balance sheet for upcoming milestones.

Ainsworth Game Technology’s FY25 results reveal a mixed bag: a 9% dip in underlying profit to $21.1 million, a hefty $43.1 million goodwill impairment tied to North America, and a strategic pivot with a new acting CEO. Strong Asia Pacific growth and new product launches contrast with margin pressures and a shrinking cash position.